WaveMan
WaveMan · Company
TCRX · Tscan Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

TCRX TScan Therapeutics (TCRX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001783328
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
30
13F, latest reported quarter

TScan Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for TScan Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Lynx1 Capital Management LP
BUY
2025-12-23 SEC
6,232
$5.6K
-81.7%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (4 buys, 3 sales), the last on Dec 22, 2025.
  • +30.2% median (+30.9% mean) 90-day return after 4 previous buys.
  • The trade is 0.1% of the 8,019,148 shares held after it.
  • No other insider bought within 30 days.
  • 30 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Lynx1 Capital Management LP bought about $5.6K of TCRX on Dec 23, 2025; 30 funds added in the latest 13F quarter.
Lynx1 Capital Management LP
BUY
2025-12-23 SECtraded 2025-12-22
75,500
$68.0K
-81.7%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (3 buys, 3 sales), the last on Dec 19, 2025.
  • +44.4% median (+36.1% mean) 90-day return after 3 previous buys.
  • The trade is 0.9% of the 8,012,916 shares held after it.
  • No other insider bought within 30 days.
  • 30 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Lynx1 Capital Management LP bought about $68.0K of TCRX on Dec 22, 2025; 30 funds added in the latest 13F quarter.
Lynx1 Capital Management LP
BUY
2025-12-23 SECtraded 2025-12-19
80,069
$72.1K
-81.7%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (2 buys, 3 sales), the last on May 20, 2025.
  • +46.1% median (+46.1% mean) 90-day return after 2 previous buys.
  • The trade is 1.0% of the 7,937,416 shares held after it.
  • No other insider bought within 30 days.
  • 30 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Lynx1 Capital Management LP bought about $72.1K of TCRX on Dec 19, 2025; 30 funds added in the latest 13F quarter.
Lynx1 Capital Management LP
BUY
2025-05-21 SECtraded 2025-05-20
1,200,000
$1.4M
-86.8%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (1 buy, 3 sales), the last on May 19, 2025.
  • The trade is 15.1% of the 7,946,141 shares held after it.
  • No other insider bought within 30 days.
  • 30 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Lynx1 Capital Management LP bought about $1.4M of TCRX on May 20, 2025; 30 funds added in the latest 13F quarter.
Lynx1 Capital Management LP
BUY
2025-05-21 SECtraded 2025-05-19
1,388,794
$1.7M
-86.8%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on May 31, 2023.
  • The trade is 20.6% of the 6,746,141 shares held after it.
  • No other insider bought within 30 days.
  • 30 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Lynx1 Capital Management LP bought about $1.7M of TCRX on May 19, 2025, the largest insider purchase at the company since 2021; 30 funds added in the latest 13F quarter.
43 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 38 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
30 funds bought in last quarter
below 62% of Pharma & Biotech
Revenue
+266.7% year over year
more than 91% of Pharma & Biotech
Margin
-1256.8% net margin
below 88% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
4.2% of the float short (float per yahoo 2026-10-27) · 3.4 days to cover · settled 2026-10-15
more than 70% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch TCRX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-91.7%12M
-92%-61%-30%+1%2025-102025-122026-022026-042026-062026-082026-10 2025-12-19 · Lynx1 Capital Management LP bought $72.1K2025-12-22 · Lynx1 Capital Management LP bought $68.0K2025-12-23 · Lynx1 Capital Management LP bought $5.6K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns TCRX: institutional holders (13F)

13F holdings, latest reported quarter
Lynx1 Capital Management LP
16,038,296 sh
$15.7M
BVF INC/IL
5,564,290 sh
$5.5M
BAKER BROS. ADVISORS LP
2,784,792 sh
$2.7M
VANGUARD CAPITAL MANAGEMENT LLC
2,158,831 sh
$2.1M
TWO SIGMA INVESTMENTS, LP
1,949,604 sh
$1.9M

Congress trades in TCRX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

TCRX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

TCRX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$69.0K position · as of 2026-06-30
0.0%
NVIT Small Cap Value Fund
$38.2K position · as of 2026-06-30
0.0%
iShares Micro-Cap ETF
$164.2K position · as of 2026-06-30
0.0%
NVIT Multi-Manager Small Company Fund
$43.6K position · as of 2026-06-30
0.0%
SMALL CAP EQUITY FUND
$64.5K position · as of 2026-06-30
0.0%
Multi-Manager Small Cap Equity Strategies Fund
$75.0K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
7 registered trials, 5 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
2 active
1
Phase 3
1 active
4
Not applicable
2 active
What changed recently
A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Pe
2026-10-06 · Recruiting → Active Not Recruiting
Phase 3
A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Pe
2026-10-06 · Recruiting → Active Not Recruiting
Phase 1
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Pa
2026-09-16 · Recruiting → Completed
,
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 30 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

TCRX financials

Revenue growth
+266.7%
XBRL, annual
Net margin
-1256.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$7.1M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-1,655%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$118.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.47x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
-3.55x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
-95.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-50.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-59.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
-$62.8M
market value at close 2026-10-26 on 2022-03-04 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
-2,600%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$10.3M$2.8M$21.0M$13.5M
Operating income-$135.8M-$134.8M-$93.5M-$66.6M
Net income-$129.8M-$127.5M-$89.2M-$66.2M
EPS (diluted)-1.00-1.14-1.36-2.75
Operating cash flow-$135.3M-$110.8M-$61.4M-$66.5M
Cash$152.4M$178.7M$133.4M$120.0M
Long-term debt$32.5M$32.1M$26.7M$29.3M
SEC XBRL, fiscal years, as known on 2026-10-28

TCRX Stock Sonar score 5/7 axes

Find similar shapesCompare

TCRX ranks highest on growth (91st percentile) and risk and compliance (72nd), and lowest on financial health (34th), among Pharma & Biotech peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
40
Inputs
  • Return on equity-95.8% · 34 pct, sector of 545
  • Return on assets-50.1% · 44 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-59.1% · 42 pct, sector of 576
Financial health
34
Inputs
  • Debt to equity0.47x · 34 pct, sector of 352
  • Cash flow to debt-3.55x · 35 pct, sector of 371
Growth
91
Inputs
  • Revenue growth, YoY+266.7% · 91 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
38
Inputs
  • Funds adding, latest quarter30 · 38 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
72
Inputs
  • Short interest, % of float+4.2% · 62 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+5.2% · 81 pct, sector of 511
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies